BIMEKIZUMAB

Brand name:

• Bimzelx®

Pharmaceutical company:

UCB Australia Proprietary Limited

Condition/indication:
(therapeutic use)

• Chronic plaque psoriasis

PBAC Submission type:

New PBS listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2023

Related medicines:

• BIMEKIZUMAB

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

16/05/2023

Lodgement of required documentation:

24/05/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 21/06/2023

Status:

Finalised

Government processes:

Commenced on 13/07/2023

Medicine listed on the PBS:

01/10/2023 (see PBS schedule)

---